Host genetic variants influence the susceptibility and severity of several infectious diseases, and the discovery of novel genetic associations with Covid-19 phenotypes could help developing new therapeutic strategies to reduce its burden. Between May 2020 and February 2021, we used Covid-19 data released periodically by UK Biobank and performed over 400 Genome-Wide Association Studies (GWAS) of Covid-19 susceptibility (N=15,738 cases), hospitalization (N=1,916), severe outcomes (N=935) and death (N=828), stratified by ancestry and sex. In coherence with previous studies, we observed 2 independent signals at the chr3p21.31 locus (rs73062389-A, OR=1.22, P=7.64E-14 and rs13092887-A, OR=1.73, P=2.38E-8, in Europeans) modulating susceptibility and severity, respectively, and a signal influencing susceptibility at the ABO locus (rs9411378-A, OR=1.10, P =7.36E-10, in Europeans), which was more significant in men than in women (P=0.01). In addition, we detected 7 genome-wide significant signals in the last data release analyzed (on February 24th 2021), of which 4 were associated with susceptibility (SCRT2, LRMDA, chr15q24.2, MIR3681HG), 2 with hospitalization (ANKS1A, chr12p13.31) and 1 for severity (ADGRE1). Finally, we identified over 300 associations which increased in significance over time, and reached at least P<10-5 in the last data release analyzed. We replicated 2 of these signals in an independent dataset: a variant downstream of CCL3 (rs2011959) associated with severity in men, and a variant located in an ATP5PO intron (rs12482569) associated with hospitalization. These results, freely available on the GRASP portal, provide new insights on the host genetic architecture of Covid-19 phenotypes.
We developed an elaborated susceptible-infected-recovered (SIR) individual-based model (IBM) with pathogen strain drift, waning and cross immunity, implemented as a novel Java Runtime-Alterable-Model Platform (J-RAMP). This platform allows parameter values, process formulations, and scriptable runtime drivers to be easily added at the start of simulation. It includes facility for integration into the R statistical and other data analysis platforms. We selected a set of parameter values and process descriptions relevant to the current COVID-19 pandemic. These include pathogen-specific shedding, environmental persistence, host transmission and mortality, within-host pathogen mutation and replication, adaptive social distancing, and time dependent vaccine rate and strain valency specifications. Our simulations illustrate that if waning immunity outpaces vaccination rates, then vaccination rollouts may fail to contain the most transmissible strains. Our study highlights the need for adaptive vaccination rollouts, which depend on reliable real-time monitoring and surveillance of strain proliferation and reinfection data needed to ensure that vaccines target emerging strains and constrain escape mutations. Together with such data, our platform has the potential to inform the design of vaccination programs that extirpate rather than exacerbate local outbreaks. Finally, our RAMP concept promotes the development of highly flexible models that can be easily shared among researchers and policymakers not only addressing healthcare crises, but other types of environmental crises as well.
Severe COVID-19 is linked to both dysfunctional immune response and unrestrained immunopathogenesis, and it remains unclear if T cells also contribute to disease pathology. Here, we combined single-cell transcriptomics and proteomics with mechanistic studies to assess pathogenic T cell functions and inducing signals. We identified highly activated, CD16+ T cells with increased cytotoxic functions in severe COVID-19. CD16 expression enabled immune complex-mediated, T cell receptor-independent degranulation and cytotoxicity not found in other diseases. CD16+ T cells from COVID-19 patients promoted microvascular endothelial cell injury and release of neutrophil and monocyte chemoattractants. CD16+ T cell clones persisted beyond acute disease maintaining their cytotoxic phenotype. Age-dependent generation of C3a in severe COVID-19 induced activated CD16+ cytotoxic T cells. The proportion of activated CD16+ T cells and plasma levels of complement proteins upstream of C3a correlated with clinical outcome of COVID-19, supporting a pathological role of exacerbated cytotoxicity and complement activation in COVID-19.
Importance: While recent literature has shown the efficacy of the COVID-19 vaccine in preventing infection, its impact on need for emergency care/hospitalization in breakthrough infections remain unclear, particularly in regions with a high rate of variant viral strains. Objective: We aimed to determine if vaccination reduces hospital visits and severe disease in breakthrough COVID-19 infections. Design: Multicenter observational cohort analysis Setting: Eight-hospital acute care regional health system in Michigan, USA Participants: Consecutive adult patients with COVID-19 requiring emergency care (EC)/hospitalization were eligible participants. Between December 15, 2020 and April 30, 2021, 11,834 EC encounters with COVID-19 infection were included. Exposures: COVID-19 vaccination Main Outcomes and Measures: Primary endpoint was rate of COVID-19 emergency care/hospitalization encounters comparing unvaccinated (UV), partially vaccinated (PV), and fully vaccinated (FV) cases. Secondary outcome was severe disease represented as a composite outcome (ICU admission, mechanical ventilation, or in-hospital death). Demographic and clinical variables were obtained from the electronic record. Vaccination data was obtained from the Michigan Care Improvement Registry and the Centers for Disease Control vaccine tracker. Results: 10,880 (91.9%) UV, 825 (7%) PV, and 129 (1.1%) FV were included. Average age was 53.0 +/- 18.2 and 52.8% were female. Accounting for the COVID-19 vaccination population groups in Michigan, the ED encounters/hospitalizations rate relevant to COVID-19 infection was 96% lower in FV versus UV (eB:0.04,95% CI 0.03 to 0.06, p <0.001) in negative binomial regression. COVID-19 EC visits rate peaked at 22.61, 12.88, and 1.29 visits per 100000 for the UV, PV, and FV groups, respectively. In the propensity-score matching weights analysis, FV had a lower risk of composite disease compared to UV but statistically insignificant (HR 0.84 95% CI 0.52 to 1.38). Conclusions: The need for emergency care and/or hospitalization due to breakthrough COVID-19 is an exceedingly rare event in fully vaccinated patients. As vaccination has increased within our region, emergency visits amongst fully vaccinated individuals have remained low and occur much less frequently when compared to unvaccinated individuals. In cases of breakthrough COVID-19, if hospital-based treatment is required, elderly patients with significant comorbidities remain at high risk for severe outcomes regardless of vaccination status.
Acute respiratory distress syndrome (ARDS) is a life-threatening syndrome of respiratory failure and diffuse alveolar damage that results from dysregulated local and systemic immune activation, causing pulmonary vascular, parenchymal and alveolar damage. SARS-CoV-2 infection has become the dominant cause of ARDS worldwide, and emerging evidence implicates neutrophils and their cytotoxic arsenal of effector functions as central drivers of immune-mediated lung injury in COVID-19 ARDS. However, a key outstanding question is whether COVID-19 drives a unique program of neutrophil activation or effector functions that contributes to the severe pathogenesis of this pandemic illness, and whether this unique neutrophil response can be targeted to attenuate disease. Using a combination of high-dimensional single cell analysis and ex vivo functional assays of neutrophils from patients with COVID-19 ARDS compared to non-COVID ARDS (caused by bacterial pneumonia), we identified a functionally distinct landscape of neutrophil activation in COVID-19 ARDS that was intrinsically programmed during SARS-CoV-2 infection. Furthermore, neutrophils in COVID-19 ARDS were functionally primed to produce high amounts of neutrophil extracellular traps (NETs). Surprisingly, this unique pathological program of neutrophil priming escaped conventional therapy with dexamethasone, thereby revealing a promising target for adjunctive immunotherapy in severe COVID-19.
The COVID-19 global pandemic has highlighted the importance of non-pharmacological interventions (NPI) for controlling epidemics of emerging infectious diseases. Despite the importance of NPI, their implementation has been monitored in an ad hoc and uncoordinated manner, mainly through the manual efforts of volunteers. Given the absence of systematic NPI tracking, authorities and researchers are limited in their ability to quantify the effectiveness of NPI and guide decisions regarding their use during the progression of a global pandemic. To address this issue, we propose 3-stage machine learning framework called EpiTopics to facilitate the surveillance of NPI by mining the vast amount of unlabelled news reports about these interventions. Building on topic modeling, our method characterizes online government reports and media articles related to COVID-19 as a mixture of latent topics. Our key contribution is the use of transfer-learning to address the limited number of NPI-labelled documents and topic modelling to support interpretation of the results. At stage 1, we trained a modified version of the unsupervised dynamic embedded topic model (DETM) on 1.2 million international news reports related to COVID-19. At stage 2, we used the trained DETM to infer topic mixture from a small set of 2000 NPI-labelled WHO documents as the input features for predicting NPI labels on each document. At stage 3, we supply the inferred country-level temporal topics from the DETM to the pretrained document-level NPI classifier to predict country-level NPIs. We identified 25 interpretable topics, over 4 distinct and coherent COVID-related themes. These topics contributed to significant improvements in predicting the NPIs labelled in the WHO documents and in predicting country-level NPIs. Together, our work lay the machine learning methodological foundation for future research in global-scale surveillance of public health interventions. The EpiTopics code is available at GitHub: https://github.com/li-lab-mcgill/covid-npi.
High resolution mobility datasets have become increasingly available in the past few years and have enabled detailed models for infectious disease spread including those for COVID-19. However, there are open questions on how such a mobility data can be used effectively within epidemic models and for which tasks they are best suited. In this paper, we extract a number of graph-based proximity metrics from high resolution cellphone trace data from X-Mode and use it to study COVID-19 epidemic spread in 50 land grant university counties in the US. We present an approach to estimate the effect of mobility on cases by fitting an ODE based model and performing multivariate linear regression to explain the estimated time varying transmissibility. We find that, while mobility plays a significant role, the contribution is heterogeneous across the counties, as exemplified by a subsequent correlation analysis. We subsequently evaluate the metrics9 utility for case surge prediction defined as a supervised classification problem, and show that the learnt model can predict surges with 95% accuracy and 87% F1-score.
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress - Condition: Covid19
Interventions: Biological: COVI-MSC; Drug: Placebo
Sponsor: Sorrento Therapeutics, Inc.
Not yet recruiting
Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (US) - Condition: Covid19
Interventions: Biological: COVI-DROPS; Drug: Placebo
Sponsor: Sorrento Therapeutics, Inc.
Not yet recruiting
Ivermectin Treatment Efficacy in Covid-19 High Risk Patients - Condition: COVID-19
Intervention: Drug: Ivermectin 0.4mg/kg/day for 5 days
Sponsor: Clinical Research Centre, Malaysia
Not yet recruiting
To Evaluate the Safety and Efficacy of TQ Formula in Covid-19 Participants - Condition: Covid19
Intervention: Drug: Black Seed Oil Cap/Tab
Sponsor: Novatek Pharmaceuticals
Recruiting
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 “Long Haul” Pulmonary Compromise - Condition: Covid19
Intervention: Biological: COVI-MSC
Sponsor: Sorrento Therapeutics, Inc.
Not yet recruiting
Intramuscular VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19 - Condition: Covid19
Intervention: Biological: VIR-7831
Sponsors: Vir Biotechnology, Inc.; GlaxoSmithKline
Not yet recruiting
Collecting Respiratory Sound Samples From Corona Patients to Extend the Diagnostic Capability of VOQX Electronic Stethoscope to Diagnose COVID-19 Patients - Condition: COVID-19
Intervention: Diagnostic Test: Electronic stethoscope
Sponsor: Sanolla
Recruiting
The Burden of COVID-19 Survivorship - Condition: Covid19
Intervention: Other: Exercise Training
Sponsor: Mayo Clinic
Not yet recruiting
Community-based Post-exposure Prophylaxis for COVID-19 - Condition: Covid19
Interventions: Other: Guduchi Ghanvati; Other: Standard guidelines
Sponsors: NMP Medical Research Institute; Aarogyam UK; Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University; Samta Ayurveda Prakoshtha, India; Padmanabhama Ayurveda Hospital and Research Centre
Completed
Impact of Steroids on Inflammatory Response in Covid-19 - Condition: Covid19
Interventions: Drug: Dexamethasone; Drug: Methylprednisolone
Sponsor: Assiut University
Recruiting
Vitamin A Supplementation in Children With Moderate to Severe Covid-19 - Condition: Covid19
Intervention: Dietary Supplement: Vitamin A supplement
Sponsor: Shiraz University of Medical Sciences
Not yet recruiting
Detection of SARS-CoV-2 RNA in Coughed Droplets From Patients With COVID-19 - Condition: Covid19
Intervention: Device: PneumoniaCheck
Sponsors: Emory University; Georgia Tech Foundation
Recruiting
Glutamine Supplementation and Short-term Mortality in Covid-19 - Condition: Covid19
Interventions: Dietary Supplement: Standard enteral nutrition; Combination Product: Glutamine
Sponsor: Assiut University
Recruiting
Favipiravir +/- Nitazoxanide: Early Antivirals Combination Therapy in COVID-19 - Condition: Covid19
Interventions: Drug: Favipiravir; Drug: Nitazoxanide; Other: Nitazoxanide Placebo
Sponsors: Coordinación de Investigación en Salud, Mexico; University College, London; Centro de Investigacion y Estudios Avanzados del Instituto Politecnico Nacional (CINVESTAV); Universidad Autonoma de Guadalajara; Siegfried Rhein S.A. de C.V.; Strides Pharma Science Limited; Hakken Enterprise
Not yet recruiting
Epidemiologic Intelligence Network (EpI-Net) to Promote COVID-19 Testing - Condition: Covid19
Intervention: Other: Epi-Net Intervention
Sponsors: Ponce Medical School Foundation, Inc.; Duke University; Harvard School of Public Health
Recruiting
A potential antiviral activity of Esculentoside A against binding interactions of SARS-COV-2 spike protein and angiotensin converting enzyme 2 (ACE2) - The recent emergence of the novel coronavirus (SARS-CoV-2) has resulted in a devastating pandemic with global concern. However, to date, there are no regimens to prevent and treat SARS-CoV-2 virus. There is an urgent need to identify novel leads with anti-viral properties that impede viral pathogenesis in the host system. Esculentoside A (EsA), a saponin isolated from the root of Phytolacca esculenta, is known to exhibit diverse pharmacological properties, especially anti-inflammatory activity….
Efficacy and safety of Dihydroorotate dehydrogenase (DHODH) inhibitors “Leflunomide” and “Teriflunomide” in Covid-19: A narrative review - Dihydroorotate dehydrogenase (DHODH) is rate-limiting enzyme in biosynthesis of pyrimidone which catalyzes the oxidation of dihydro-orotate to orotate. Orotate is utilized in the biosynthesis of uridine-monophosphate. DHODH inhibitors have shown promise as antiviral agent against Cytomegalovirus, Ebola, Influenza, Epstein Barr and Picornavirus. Anti-SARS-CoV-2 action of DHODH inhibitors are also coming up. In this review, we have reviewed the safety and efficacy of approved DHODH inhibitors…
Therapeutic targets of natural products for the management of cardiovascular symptoms of coronavirus disease 2019 - The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first occurred in China in December 2019 and subsequently spread all over the world with cardiovascular, renal, and pulmonary symptoms. Therefore, recognizing and treating the cardiovascular sign and symptoms that caused by coronavirus disease 2019 (COVID-19) can be effective in reducing patient mortality. To control the COVID-19-related cardiovascular symptoms, natural products are considered one of the promising…
SARS-CoV-2 Nonstructural Protein 1 Inhibits the Interferon Response by Causing Depletion of Key Host Signaling Factors - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic. While previous studies have shown that several SARS-CoV-2 proteins can antagonize the interferon (IFN) response, some of the mechanisms by which they do so are not well understood. In this study, we describe two novel mechanisms by which SARS-CoV-2 blocks the IFN pathway. Type I IFNs and IFN-stimulated genes (ISGs) were poorly induced during SARS-CoV-2…
Mechanism of Inhibition of the Reproduction of SARS-CoV-2 and Ebola Viruses by Remdesivir - Remdesivir is an antiviral drug initially designed against the Ebola virus. The results obtained with it both in biochemical studies in vitro and in cell line assays in vivo were very promising, but it proved to be ineffective in clinical trials. Remdesivir exhibited far better efficacy when repurposed against SARS-CoV-2. The chemistry that accounts for this difference is the subject of this study. Here, we examine the hypothesis that remdesivir monophosphate (RMP)-containing RNA functions as a…
Punicalagin and zinc (II) ions inhibit the activity of SARS-CoV-2 3CL-protease in vitro - CONCLUSIONS: We suggest that these compounds could be used as potential antiviral drugs against COVID-19.
In Silico Evaluation of Cyclophilin Inhibitors as Potential Treatment for SARS-CoV-2 - CONCLUSIONS: Despite CsA’s promising antiviral characteristics, the interactions between cyclophilins and coagulation factors emphasize risk stratification for COVID patients with thrombosis dispositions.
The Therapeutic Potential of Galectin-3 in the Treatment of Intrahepatic Cholangiocarcinoma Patients and Those Compromised With COVID-19 - The novel coronavirus pneumonia COVID-19 is characterized by all age susceptibility, which imposes a dramatic threat to the human species all over the world. According to current available data, the cytokine storm appears to be the most life-threatening symptom of severe COVID-19 cases accompanied with lung fibrosis. Galectin-3 (Gal-3), a member of soluble β-galactoside-binding lectin families, has been implicated as a key regulator in various inflammation conditions in addition to its…
Simple rapid in vitro screening method for SARS-CoV-2 anti-virals that identifies potential cytomorbidity-associated false positives - CONCLUSIONS: We describe the methodology for a simple in vitro drug screening assay that identifies potential anti-viral drugs via their ability to inhibit SARS-CoV-2-induced CPE. The additional growth assay illustrated how several drugs display anti-viral activity at concentrations that induce cytomorbidity. For instance, hydroxychloroquine showed anti-viral activity at concentrations that slow cell growth, arguing that its purported in vitro anti-viral activity arises from non-specific…
N-(4-Hydroxyphenyl) retinamide suppresses SARS-CoV-2 spike protein-mediated cell-cell fusion by a dihydroceramide delta4-desaturase 1-independent mechanism - The membrane fusion between the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and host cells is essential for the initial step of infection; therefore, the host cell membrane components, including sphingolipids, influence the viral infection. We assessed several inhibitors of the enzymes pertaining to sphingolipid metabolism, against SARS-CoV-2 spike protein (S)-mediated cell-cell fusion and viral infection. N-(4-hydroxyphenyl) retinamide (4-HPR), an inhibitor of dihydroceramide…
Investigating the active compounds and mechanism of HuaShi XuanFei formula for prevention and treatment of COVID-19 based on network pharmacology and molecular docking analysis - Traditional Chinese medicine (TCM) has exerted positive effects in controlling the COVID-19 pandemic. HuaShi XuanFei Formula (HSXFF) was developed to treat patients with mild and general COVID-19 in Zhejiang Province, China. The present study seeks to explore its potentially active compounds and pharmacological mechanisms against COVID-19 based on network pharmacology, molecular docking, and molecular dynamics (MD) simulation. All components of HSXFF were harvested from the pharmacology database…
Convalescent plasma therapy in patients with moderate-to-severe COVID-19: A study from Indonesia for clinical research in low- and middle-income countries - BACKGROUND: We explored the outcome of convalescent plasma (CP) treatment in patients with moderate and severe coronavirus disease 2019 (COVID-19) and investigated variables for the design of further trials in Indonesia.
Is there any role of intermittent fasting in the prevention and improving clinical outcomes of COVID-19?: intersection between inflammation, mTOR pathway, autophagy and calorie restriction - The coronavirus disease 2019 (COVID-19) pandemic is provoking a global public health crisis. Even though the academic world is intensively pursuing new therapies, there is still no “game changer” in the management of COVID 19. The Mammalian Target of Rapamycin (mTOR) is an ancient signaling system that has been proposed as a molecular tool used by coronaviruses and other RNA and DNA viruses in order to replicate and persist in the host cell. In recent years, Intermittent Fasting (IF), a practice…
Screening of world approved drugs against highly dynamical spike glycoprotein of SARS-CoV-2 using CaverDock and machine learning - The new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes pathological pulmonary symptoms. Most efforts to develop vaccines and drugs against this virus target the spike glycoprotein, particularly its S1 subunit, which is recognised by angiotensin-converting enzyme 2. Here we use the in-house developed tool CaverDock to perform virtual screening against spike glycoprotein using a cryogenic electron microscopy structure (PDB-ID: 6VXX) and the representative structures of five…
Alkaloids as Potential Phytochemicals against SARS-CoV-2: Approaches to the Associated Pivotal Mechanisms - Since its inception, the coronavirus disease 2019 (COVID-19) pandemic has infected millions of people around the world. Therefore, it is necessary to find effective treatments against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), as it is the viral source of COVID-19. Alkaloids are one of the most widespread plant-derived natural compounds with prominent antiviral effects. Accordingly, these phytochemicals have been promising candidates towards discovering effective treatments…
폐마스크 밀봉 회수기 - 본 발명은 마스크 착용 후 버려지는 일회용 폐마스크를 비닐봉지에 넣은 후 밀봉하여 배출함으로써, 2차 감염을 예방하고 일반 생활폐기물과 선별 분리 배출하여 환경오염을 방지하는 데 그 목적이 있다. - link
COST EFFECTIVE PORTABLE OXYGEN CONCENTRATOR FOR COVID-19 - - link
METHOD OF IDENTIFYING SEVERE ACUTE RESPIRATORY SYNDROME CORONA VIRUS 2 (SARS-COV-2) RIBONUCLEIC ACID (RNA) - - link
IMPROVEMENTS RELATED TO PARTICLE, INCLUDING SARS-CoV-2, DETECTION AND METHODS THEREFOR - - link
DEEP LEARNING BASED SYSTEM FOR DETECTION OF COVID-19 DISEASE OF PATIENT AT INFECTION RISK - The present invention relates to Deep learning based system for detection of covid-19 disease of patient at infection risk. The objective of the present invention is to solve the problems in the prior art related to technologies of detection of covid-19 disease using CT scan image processing. - link
Wiederverwendbare Maske, mit einem Maskenkörper (100), einem Fixierband (300) zum Befestigen des Maskenkörpers (100) an einem menschlichen Gesicht, einer auswechselbaren Schicht (200), die zwischen dem menschlichen Gesicht und dem Maskenkörper (100) angeordnet ist, und einem Fixierteil (400) zum Fixieren der auswechselbaren Schicht auf dem Maskenkörper (100).
A COMPREHENSIVE DISINFECTION SYSTEM DURING PANDEMIC FOR PERSONAL ITEMS AND PROTECTIVE EQUIPMENT (PPE) TO SAFEGUARD PEOPLE - The current Covid-19 pandemic has led to an enormous demand for gadgets / objects for personal protection. To prevent the spread of virus, it is important to disinfect commonly touched objects. One of the ways suggested is to use a personal UV-C disinfecting box that is “efficient and effective in deactivating the COVID-19 virus. The present model has implemented the use of a UV transparent material (fused silica quartz glass tubes) as the medium of support for the objects to be disinfected to increase the effectiveness of disinfection without compromising the load bearing capacity. Aluminum foil, a UV reflecting material, was used as the inner lining of the box for effective utilization of the UVC light emitted by the UVC lamps. Care has been taken to prevent leakage of UVC radiation out of the system. COVID-19 virus can be inactivated in 5 minutes by UVC irradiation in this disinfection box - link
UBIQUITOUS COMPUTING SYSTEM FOR MENTAL HEALTH MONITORING OF PERSON DURING THE PANDEMIC OF COVID-19 - - link
一种预判重症新冠肺炎(COVID-19)的标志物及其产品和用途 - 本发明提供了一种预判重症疾病的标志物,所述的预判重症疾病的标志物为S100A12,序列为SEQ ID NO.1,所述的重症疾病为重症新冠肺炎、重症感染中的一种。S100A12基因作为标志物,在预判重症疾病时对全血中的S100A12基因的表达水平进行检测即可,无需对白细胞进行分离,简化检测流程。S100A12的表达水平可以指导感染类疾病包括新冠肺炎重症的预判,从而及早施治,降低病死率,具有很好的临床应用前景。 - link
一种新型冠状病毒COVID-19-S1蛋白的表达和纯化方法 - 本发明属于生物技术领域,具体涉及一种新型冠状病毒COVID‑19‑S1蛋白的表达和纯化方法。本发明提供的方法,主要包括构建COVID‑19‑S1蛋白表达质粒、将COVID‑19‑S1蛋白表达质粒转化、培养表达COVID‑19‑S1蛋白、纯化COVID‑19‑S1蛋白等过程。本发明将能在293F细胞中高分泌表达蛋白的信号肽与Kozak区和编码人COVID‑19‑S1蛋白的基因进行重组,来提高目的蛋白的表达量和分泌量。采用本发明提供的方法,可以解决新型冠状病毒COVID‑19‑S1蛋白分泌量低、纯度低的问题,为免疫学快速诊断、制备单抗、开展解析蛋白结构研究等提供物质基础。 - link